Corticosteroid News and Research RSS Feed - Corticosteroid News and Research

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.
Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. [More]
Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). [More]
LABA-ICS combination therapy better than LABAs alone for COPD

LABA-ICS combination therapy better than LABAs alone for COPD

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a lower risk of death or COPD hospitalization, according to a study in the September 17 issue of JAMA. [More]
New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma. [More]
Asthma medication adherence strategies identified

Asthma medication adherence strategies identified

Keeping asthma medication in the bathroom and incorporating its use into daily routines are strategies associated with good medication adherence in older adults with asthma, US research shows. [More]
Clinical study shows long-term effectiveness of Orthocell’s Ortho-ATI™ for treatment resistant tennis elbow

Clinical study shows long-term effectiveness of Orthocell’s Ortho-ATI™ for treatment resistant tennis elbow

Regenerative medicine company Orthocell Limited has today released results from a long-term clinical study into its Ortho-ATI™ treatment for tennis elbow that provides evidence of the durability and long term success of this treatment. [More]
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]
Physiological variables best predict adult asthma phenotypes

Physiological variables best predict adult asthma phenotypes

Physiological variables are more consistent predictors of adult asthma phenotypes than inflammatory biomarkers, an international team of researchers suggests. [More]
Only 52% of women receive low-cost treatment to prevent babies death

Only 52% of women receive low-cost treatment to prevent babies death

A major international study of more than 303 000 births in 29 low-income and middle-income countries has found that only half (52%) of women who are eligible to receive a simple, effective, low-cost treatment to prevent death and disability in their newborn babies are getting it. [More]

Study provides care coaches with useful ideas to help older patients improve asthma medication rituals

Storing it in the bathroom and making it part of a daily routine may be helpful advice that doctors can give their older asthmatic patients who struggle to remember to take their daily prescribed medication. [More]
Artesunate drug can be used to control asthma, finds NUS study

Artesunate drug can be used to control asthma, finds NUS study

Asthmatic patients may soon have a more effective way to control the condition, thanks to a new pharmacological discovery by researchers from the National University of Singapore. [More]
Common herbal-based anti-malarial drug can be used to control asthma, shows study

Common herbal-based anti-malarial drug can be used to control asthma, shows study

Asthmatic patients may soon have a more effective way to control the condition, thanks to a new pharmacological discovery by researchers from the National University of Singapore (NUS). [More]
Long-acting inhaled combination therapy best for COPD

Long-acting inhaled combination therapy best for COPD

The combination of a long-acting β22-agonist and an inhaled corticosteroid may be the best choice for some patients with chronic obstructive pulmonary disease who need more than short-acting bronchodilators, suggest the results of a Cochrane Collaboration network meta-analysis. [More]
Study: Dietary elimination is successful method of treatment for adults with EoE

Study: Dietary elimination is successful method of treatment for adults with EoE

Dietary elimination is a successful method of treatment for adults with eosinophilic esophagitis (EoE), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Scientists identify genes that may help predict steroid responsiveness in people with EoE

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. [More]
Asthma inhalers may suppress children's growth

Asthma inhalers may suppress children's growth

Corticosteroid drugs that are given by inhalers to children with asthma may suppress their growth, evidence suggests. Two new systematic reviews published in The Cochrane Library focus on the effects of inhaled corticosteroid drugs (ICS) on growth rates. [More]
Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Research: TB infection among people taking corticosteroid pills may be underestimated

Research: TB infection among people taking corticosteroid pills may be underestimated

Tuberculosis infection among people taking corticosteroid pills may be underestimated, new research suggests. [More]